Biomarker Consortium

GI Cancer

Hepatocellular Carcinoma

The rearranged during transfection (RET) protein is a tyrosine kinase involved in multiple cellular processes, including proliferation, differentiation, survival, motility, and migration.

 There are 4 known endogenous ligands, including glial cell line-derived neurotrophic factor (GDNF), neurturin, artemin, and persephin.

 Ligands bind to glycosylphosphatidylinositol-anchored co-receptor molecules, called GFRα, and the co-receptor complex presents to RET, inducing homodimerization.

 Homodimerized RET causes autophosphorylation, which activates signal transduction pathways RAS-MAPK, JAK-STAT, PKC, PI3K-AKT, PLCγ, and PKC.

gene is located on chromosome 10 and encodes a transmembrane tyrosine kinase and proto-oncogene.

 RET contains intracellular, transmembrane, and extracellular domains.

The extracellular region contains cysteine-rich domains and cadherin-like domains (involved in dimerization and are, thus, mutation targets.

Hepatocellular carcinoma (HCC) patients with 

 gene fusion have a poorer duration of response and overall survival compared to wild-type tumors.

 rearrangement likely occurs because of broken repair mechanisms after DNA double-strand breaks, which can occur via cell-extrinsic or cell-intrinsic factors.

Breakpoints occur more frequently at intron 11, but some involve introns 7 and 10.

 In some cases, the partner fusion gene is constitutively expressed, so RET tyrosine kinase activity is increased.

 In other cases, the fusion contains a dimerization domain that activates RET in a ligand-independent manner.

National Comprehensive Cancer Network guidelines currently have no established indication for molecular profiling in HCC, but it may be warranted in some instances with unusual or atypical presentation.

 RNA-sequencing next-generation sequencing (NGS) has high sensitivity and specificity and can detect RET expression, while other testing modalities currently have limited utility.

 In cases where NGS is unavailable, the European Society for Medical Oncology (ESMO) recommends fluorescence in situ hybridization or reverse transcription polymerase chain reaction (RT-PCR).

Selpercatinib is FDA-approved for the treatment of patients with locally advanced or metastatic HCC solid tumors with a 

gene fusion who have progressed on or following prior systemic treatment or who have no satisfactory alternative treatment options.

 It is a selective tyrosine kinase inhibitor that inactivates wild-type 

Selpercatinib is approved under accelerated approval based on the results of the phase I/II study LIBRETTO-001 (NCT03157128).

 Among 41 patients with advanced solid tumors, the overall response rate was 44% with a median duration of response of 24.5 months, and 67% of patients had a response at 6 months or longer.

 Selpercatinib was well tolerated, with only 8% of patients discontinuing permanently due to an adverse reaction.

Zhao L, Wang N, Zhang D, Jia Y, Kong F. A comprehensive overview of the relationship between RET gene and tumor occurrence. 

. 2023;13:1090757. doi:10.3389/fonc.2023.1090757

Belli C, Penault-Llorca F, Ladanyi M, et al. ESMO recommendations on the standard methods to detect RET fusions and mutations in daily practice and clinical research. 

. 2021;32(3):337-350. doi:10.1016/j.annonc.2020.11.021

Carlomagno F. Thyroid cancer: role of RET and beyond. 

Drilon A, Hu ZI, Lai GGY, Tan DSW. Targeting RET-driven cancers: lessons from evolving preclinical and clinical landscapes. 

. 2018;15(3):151-167. doi:10.1038/nrclinonc.2017.175

Hua S. Physiological and pharmaceutical considerations for rectal drug formulations. 

. 2019;10:1196. doi:10.3389/fphar.2019.01196

Kato S, Subbiah V, Marchlik E, Elkin SK, Carter JL, Kurzrock R. RET aberrations in diverse cancers: next-generation sequencing of 4,871 patients. 

. 2017;23(8):1988-1997. doi:10.1158/1078-0432.CCR-16-1679

Ye S, Zhao XY, Hu XG, et al. TP53 and RET may serve as biomarkers of prognostic evaluation and targeted therapy in hepatocellular carcinoma. 

. 2017;37(4):2215-2226. doi:10.3892/or.2017.5494

NCCN guidelines version 1.2024: hepatocellular carcinoma

. https://www.nccn.org/professionals/physician_gls/pdf/hcc.pdf

RETEVMO (selpercatinib). Prescribing information. Eli Lilly and Company; 2022. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/213246s008lbl.pdf

Subbiah V, Wolf J, Konda B, et al. Tumour-agnostic efficacy and safety of selpercatinib in patients with RET fusion-positive solid tumours other than lung or thyroid tumours (LIBRETTO-001): a phase 1/2, open-label, basket trial. 

. 2022;23(10):1261-1273. doi:10.1016/S1470-2045(22)00541-1

FDA D.I.S.C.O. burst edition: FDA approvals of Retevmo (selpercatinib) for adult patients with locally advanced or metastatic RET fusion-positive solid tumors, and Retevmo (selpercatinib) for adult patients with locally advanced or metastatic RET fusion-positive non-small cell lung cancer. FDA. Updated November 7, 2022. Accessed April 1, 2024. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-disco-burst-edition-fda-approvals-retevmo-selpercatinib-adult-patients-locally-advanced-or

Blinatumomab consolidation improved MRD clearance over chemotherapy in DS B-ALL patients, according to ALLTogether1 DS study results.

Frontline Blinatumomab Demonstrates “Impressive” Activity in Down Syndrome B-ALL

Biomarkers

Disparities in Cancer Care

Global Oncology

Biosimilars

Brain Cancer

HER2+ Breast Cancer

Breast Cancer

Oncology Business Management

Precision Medicine in Oncology®

CAR T-cell Therapy

COVID-19

Pancreatic Cancer

Gastric Cancer

Colorectal Cancer

Gastrointestinal Cancer

Urothelial Cancer

Prostate Cancer

Genitourinary Cancers

Ovarian Cancer

Gynecologic Oncology

Head & Neck Cancers

Chronic Lymphocytic Leukemia

Non-Hodgkin Lymphoma

Mantle Cell Lymphoma

Multiple Myeloma

Myeloproliferative Neoplasms

Hematologic Oncology

Immuno-Oncology

Lung Cancer

Melanoma & Skin Cancer

Pediatric Oncology

Sarcomas

Supportive Care

Sanjay Popat, BSc, MBBS, FRCP, PhD, discusses OS data with amivantamab plus chemotherapy in EGFR-mutated, advanced NSCLC after progression on osimertinib.

Dr Popat on OS Outcomes With Amivantamab Plus Chemotherapy in EGFR-Mutated, Advanced NSCLC

Darolutamide plus ADT shows PFS benefit without docetaxel in metastatic hormone-sensitive prostate cancer.

Darolutamide Plus ADT Improves rPFS in mHSPC

Frontline abemaciclib plus ET demonstrated a superior ORR vs chemotherapy in HR+/HER2– advanced breast cancer with aggressive disease characteristics.

Abemaciclib/ET Combo Improves Responses vs Chemo in Aggressive HR+/HER2– Breast Cancer

Lutetium Lu 177 dotatate shows consistent efficacy over high-dose octreotide in advanced GEP-NETs, according to data from the NETTER-2 trial. 

Multivariate Analysis Provides Additional Insight on Efficacy of 177Lu-Dotatate in GEP-NETs

News

OncClub

All Oncology News

Pipeline Report

Media

Insights

MedNews Week

Medical World News

OncChats

OncLive News Network®

OncLive TV

Peer Exchange

Podcasts

Rapid Readouts

The Talk

Conferences

Conference Coverage

Conference Listing

Events

Giants of Cancer Care

PER Events

Scientific Interchanges

State of the Science Summit / IPC

Webinars

Partners

Publications

Oncology Live®

Oncology Fellows

Supplements and Featured Publications

All Publications

CME/CE

Resources

Interactive Tools

Learning Modules

Presentations

Subscribe

Articles

 
Kristi Rosa joined MJH Life Sciences in 2016 and has since held several positions within the company. She helped launch the rapidly growing infectious disease news resource 

. Prior to working at the company, she served as lead copywriter and marketing coordinator at The Strand Theater. Email: krosa@onclive.com


Gina Mauro is your lead editorial contact for 

. She joined the company in 2015 and has held various positions on 

; she is also the on-air correspondent for 

. Prior to joining MJH Life Sciences, she worked at Gannett as a full-time reporter with the Asbury Park Press. Email: gmauro@onclive.com 

Tremelimumab plus durvalumab sustained an overall survival improvement in  unresectable hepatocellular carcinoma.

Durvalumab/Tremelimumab Sustains OS Benefit in Unresectable HCC

OncLive serves as the connection to oncology, including groundbreaking cancer news and interviews with top oncologists in multimedia formats.